当前位置: X-MOL 学术Int. Clinical Psychopharmacol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Benefit of long-acting paliperidone in Huntington's disease: a case report.
International Clinical Psychopharmacology ( IF 2.1 ) Pub Date : 2021-03-01 , DOI: 10.1097/yic.0000000000000346
Hervé Javelot 1, 2 , Mylène Meyer 3, 4 , Solène Frismand 3, 4 , Coraline Hingray 3, 5
Affiliation  

Through this brief report, we described our clinical considerations about the treatment of motor fluctuations and psychiatric comorbidities in Huntington's disease, for example, aggressiveness and obsessive-compulsive disorders. Indeed, as classical treatment, for example, olanzapine and risperidone, were inefficient to improve motor disorders in our patient, we postulated that motor fluctuations could be influenced by the pharmacokinetic profile of oral risperidone. So, in line with recent practice in schizophrenia, we proposed empirically paliperidone 1-month long-acting injections hypothesized to improve motor fluctuations, treatment so far reserved to Huntington's disease patients who are noncompliant to oral risperidone. Improvement was soon observed concerning motor fluctuations, but also aggressiveness, supporting our initial hypothesis.

中文翻译:

长效帕潘立酮在亨廷顿舞蹈病中的益处:一例病例报告。

通过这份简短的报告,我们描述了有关治疗亨廷顿氏病中的运动波动和精神病合并症(例如攻击性和强迫症)的临床考虑。确实,由于奥氮平和利培酮等经典疗法在改善我们患者的运动障碍方面无能为力,因此我们推测运动波动可能受口服利培酮的药代动力学影响。因此,根据最近在精神分裂症中的实践,我们提出了以经验为基础的帕潘立酮1个月长效注射剂,据推测可改善运动波动,到目前为止,该疗法仅适用于不符合口服利培酮治疗的亨廷顿氏病患者。很快观察到有关运动波动和攻击性的改善,
更新日期:2021-03-01
down
wechat
bug